Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated NASDAQ: VRTX. In a filing disclosed on March 09th, the Representative disclosed that they had bought between $15,001 and $50,000 in Vertex Pharmaceuticals stock on February 24th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $15,001 - $50,000 in shares of RTX NYSE: RTX on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of Royal Gold NASDAQ: RGLD on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of QUALCOMM NASDAQ: QCOM on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 2/24/2025.
- Sold $15,001 - $50,000 in shares of Norfolk Southern NYSE: NSC on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 2/24/2025.
- Purchased $50,001 - $100,000 in shares of AbbVie NYSE: ABBV on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of Johnson & Johnson NYSE: JNJ on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of The Cigna Group NYSE: CI on 2/24/2025.
- Purchased $15,001 - $50,000 in shares of Adobe NASDAQ: ADBE on 2/24/2025.
Vertex Pharmaceuticals Price Performance
NASDAQ VRTX traded up $6.13 during trading hours on Wednesday, reaching $494.47. 482,082 shares of the company's stock were exchanged, compared to its average volume of 1,467,597. The firm has a fifty day moving average of $451.99 and a 200-day moving average of $461.34. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The stock has a market cap of $126.98 billion, a PE ratio of -224.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the completion of the sale, the executive vice president now owns 58,539 shares in the company, valued at $27,825,928.26. This trade represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 1,084 shares of company stock valued at $505,512 in the last 90 days. 0.20% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on VRTX. StockNews.com upgraded shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday. Canaccord Genuity Group raised Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and upped their price objective for the stock from $408.00 to $424.00 in a report on Tuesday, February 11th. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. JPMorgan Chase & Co. dropped their target price on Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating for the company in a research report on Monday, December 23rd. Finally, Morgan Stanley raised their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an "equal weight" rating in a report on Tuesday, February 11th. Ten research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $506.70.
Check Out Our Latest Report on Vertex Pharmaceuticals
Hedge Funds Weigh In On Vertex Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VRTX. Dunhill Financial LLC lifted its position in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $30,000. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth about $33,000. Truvestments Capital LLC acquired a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $35,000. Finally, Sugar Maple Asset Management LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $35,000. 90.96% of the stock is owned by institutional investors and hedge funds.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
About Vertex Pharmaceuticals
(
Get Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Stories
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
